Effectiveness of Abrocitinib in Cyclosporine-Resistant Atopic Dermatitis: A Real-world Experience from the Indian Subcontinent
Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by pruritus and eczematous lesions. Abrocitinib, a selective Janus kinase 1 (JAK1) inhibitor, has recently been approved in India for moderate-to-severe AD in adults. This prospective real-world case series evaluated the eff...
Збережено в:
| Автори: | , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Wolters Kluwer Medknow Publications
2026-05-01
|
| Серія: | Indian Journal of Dermatology |
| Предмети: | |
| Онлайн доступ: | https://journals.lww.com/10.4103/ijd.ijd_516_25 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|